Clinical trials: Depressive Disorder, Major
Nicotine Dependence, Major Depressive Disorder
Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers
Persons who struggle with depression smoke at high rates and experience low quit rates in treatment. The best way to improve cessation treatment for this underserved population remains unknown.
- Trial name
- NCT02378714
- Testing
- Varenicline, BASC, Standard treatment
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Northwestern University
Depression
Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)
Trial to determine the maximum tolerated dose (MTD) based on safety and tolerability of MK-8777 (Org 26576, SCH 900777) in participants with major depressive disorder.
- Trial name
- NCT00610649
- Testing
- MK-8777
- Volunteers
- 54 people
- Sponsor
- Merck Sharp & Dohme LLC
Major Depressive Disorder, Alcohol Use Disorder
Treatment of Young Adults With Comorbid AUD/MDD: A Pilot Medication Trial
Recent reports have shown that alcohol misuse is a particularly serious problem among the 18 to 25 year old age group. Previous medication trials with SSRI antidepressants among young adults with co-occurring depressive…
- Trial name
- YAAD-P (NCT02646449)
- Testing
- Mirtazapine
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Major Depressive Disorder, Depression
rTMS for MDD: 5.5cm Rule vs. F3 Targeting
The purpose of this study is to examine the effects of different treatment locations using repetitive transcranial magnetic stimulation (rTMS) to treat major depressive disorder.
- Trial name
- NCT03378570
- Testing
- Repetitive transcranial magnetic stimulation
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- Nicholas Trapp
Major Depressive Disorder
Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to determine the long-term efficacy and safety of vortioxetine, once daily (QD), in adults with major depressive disorder.
- Trial name
- NCT00707980
- Testing
- Vortioxetine
- Where
- 92 sites in United States, Australia and 15 more
- Volunteers
- 836 people
- Sponsor
- Takeda
Major Depressive Disorder
Iloperidone Augmentation of SSRIs for Patients With Major Depressive Disorder With Residual Anger and Irritability
Iloperidone is an atypical antipsychotic drug, FDA-approved for the acute treatment of schizophrenia in adults in 2009 (Marino et al., 2010); moreover, some of its pharmacological features seem to be very promising in treating…
- Trial name
- NCT01464229
- Testing
- Iloperidone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Maurizio Fava, MD
Bipolar Disorder
FMRI Study of Brain Response Before and After Lithium Treatment in People With Bipolar Disorder
This study will assess the effects of bipolar disorder on brain activity and will determine if medication changes the brain activity in people with bipolar disorder.
- Trial name
- NCT00596622
- Testing
- Lithium
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Indiana University
Major Depressive Disorder
VA Augmentation and Switching Treatments for Improving Depression Outcomes
The overall purpose is to determine research based 'next-steps' for outpatients with major depressive disorder who have not had satisfactory outcomes to standard 'first-step' treatments.
- Trial name
- VAST-D (NCT01421342)
- Testing
- Switching: Bupropion-SR, Augmenting: Antidepressant + Bupropion-SR, Augmenting: Antidepressant + Aripiprazole
- Where
- 35 sites in United States
- Volunteers
- 1,522 people
- Sponsor
- VA Office of Research and Development
MDD, Citalopram
Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression
Primarily, this study seeks to evaluate whether citalopram treatment is associated with an increase in the Glutamine (Gln)/Glutamate (Glu) ratio in the anterior cingulate cortex (ACC) from baseline to day 3 of treatment.
- Conditions
- MDD, Citalopram, Major Depressive Disorder
- Trial name
- NCT01557946
- Testing
- citalopram
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Mclean Hospital
Major Depressive Disorder
Mini Theta Burst TMS in MDD Patients
This is not a treatment study. In this study, the researchers are primarily interested in examining whether functional MRI (fMRI)-guided transcranial magnetic stimulation (TMS) may be more effective than traditional TMS methods…
- Trial name
- NARSAD (NCT04014959)
- Testing
- Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Pennsylvania
Major Depressive Disorder
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms.
- Trial name
- NCT01436162
- Testing
- Antidepressant + SPD489 (Lisdexamfetamine dimesylate )
- Where
- 101 sites in United States, Belgium and 9 more
- Volunteers
- 1,105 people
- Sponsor
- Shire
Depressive Disorder, Treatment-Resistant
Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression
This study evaluated the efficacy and safety of the compound MIJ821 compared to placebo in patients aged from 18 to 65 years diagnosed with treatment-resistant depression. The study was conducted in the US and in Europe (Spain).
- Trial name
- NCT03756129
- Testing
- MIJ821, Ketamine
- Where
- 12 sites in United States, Spain
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Major Depressive Disorder
A Phase 2 Trial of OPC-64005 for Major Depressive Disorder
The objective of the trial is to compare the efficacy of OPC-64005 at 20 mg vs placebo and to assess the safety and pharmacokinetics of OPC-64005 at 10 and 20 mg in patients with major depressive disorder (MDD).The primary…
- Trial name
- NCT04244253
- Testing
- OPC-64005 20 mg , Once-daily, OPC-64005 10 mg , Once-daily
- Where
- Japan
- Volunteers
- 273 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizoaffective Disorder, Schizophrenia
Effectiveness of a Mobile Texting Intervention for People With Serious Mental Illness
Testing an mHealth mobile interventionist texting program on illness management.
- Conditions
- Schizoaffective Disorder, Schizophrenia, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT03062267
- Testing
- Mobile Interventionist
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- University of Washington
Major Depressive Disorder
A Study of LY2216684 in Healthy Participants
This study will evaluate the pharmacodynamic and pharmacokinetic interaction of LY2216684 with alcohol in healthy participants. This study will run approximately for 34 days.
- Trial name
- NCT01380691
- Testing
- LY2216684, Alcoholic beverage
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Treatment Resistant Depression
KET-RO Plus RO DBT for Treatment Resistant Depression
This pilot study will assess the safety and feasibility of intravenous (IV) ketamine combined with RO DBT in young adults with Treatment-Resistant Depression (TRD).
- Trial name
- KET-RO (NCT06138691)
- Testing
- Ketamine Infusion plus RO DBT
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder
Clinical Study of Generic and Brand Bupropion in Depression
Determine bioequivalence between branded and generic bupropion extended release (XL) products (and between generic products) at steady state in patients with major depressive disorder.
- Trial name
- BALANCE (NCT02209597)
- Testing
- Bupropion XL 300
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder
A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder
This is a study on the effectiveness, tolerability and safety of oral ziprasidone as monotherapy in patients with major depressive disorder (MDD).
- Trial name
- Geodon (NCT00555997)
- Testing
- Ziprasidone
- Where
- 7 sites in United States
- Volunteers
- 120 people
- Sponsor
- Massachusetts General Hospital
Depression, Major Depressive Disorder
Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine
The purposes of this project are to examine the feasibility, safety, tolerability and clinical effect of low-dose buprenorphine as a novel treatment for late-life treatment-resistant depression and to develop preliminary data…
- Trial name
- IRLGREY-B (NCT02176291)
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Jordan F. Karp
Major Depressive Disorder (MDD)
Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone
This is an 8-week, randomized, double blind, parallel group, 3-arm trial to compare 10 mg/day, 20 mg/day and 40 mg/day as starting doses of vilazodone following a switch from generic SSRIs and SNRIs.
- Trial name
- NCT02015546
- Testing
- Vilazodone
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Duke University